A amyloid-β (Aβ) plaque formation in the brain is known to be the root cause of Alzheimer’s disease
(AD), which affects the behavior, memory, and cognitive ability in humans. The brain starts undergoing
changes several years before the actual appearance of the symptoms. Nanotechnology could prove to be an alternative
strategy for treating the disease effectively. It encompasses the diagnosis as well as the therapeutic aspect
using validated biomarkers and nano-based drug delivery systems, respectively. A nano-based therapy
may provide an alternate strategy, wherein one targets the protofibrillar amyloid-β (Aβ) structures, and this is
followed by their disaggregation as random coils. Conventional/routine drug therapies are inefficient in crossing
the blood-brain barrier; however, this hurdle can be overcome with the aid of nanoparticles. The present review
highlights the various challenges in the diagnosis and treatment of AD. Meticulous and collaborative research
using nanotherapeutic systems could provide remarkable breakthroughs in the early-stage diagnosis and
therapy of AD.
Keywords: Amyloid-β, alzheimer`s, nanoparticles, drug delivery system, drug therapy, diagnosis, neurodegeneration.
Rights & PermissionsPrintExport